Brilique (ticagrelor)
- Region
- 🇪🇺 EU
- Active substance
- ticagrelor
- Company
- AstraZeneca AB
- Status
- Authorised
- Therapeutic area
- Peripheral Vascular Diseases; Acute Coronary Syndrome
- EU approval
- Fri 03 Dec 2010
- Application
- EMEA/H/C/001241
- ATC
- B01AC24
- Official record
- www.ema.europa.eu
Indication
Brilique, co administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with acute coronary syndromes (ACS) or a history of myocardial infarction (MI) and a high risk of developing an atherothrombotic event Brilique, co-administered with acetyl salicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with a history of myocardial infarction (MI occurred at least one year ago) and a high risk of developing an atherothrombotic event.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Possia Withdrawn · AstraZeneca AB
Follow Brilique
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.